Biodesix seeks to raise up to $79M from public in IPO

BOULDER — Lung cancer testing company Biodesix Inc. is seeking to raise as much as $79 million in its initial public offering and values itself at up to $500 million on the open market.

In an updated S-1 filing with the U.S. Securities and Exchange Commission Wednesday, the Boulder company said it plans to distribute 4,166,667 shares of common stock upon its debut on the Nasdaq and anticipates initial prices of between $17 and $19 per share.

At that range, Biodesix would raise between $70.83 million and $79.16 million from sales to the public.

However,…